However, a study was initiated to investigate the effect of the oral TLR8 agonist Selgantolimod on HBsAg in participants with both chronic HBV and HIV infections (ClinicalTrials.gov Identifier: NCT05551273), which may provide new data. The gene discussed is TLR8; the disease is HIV infectious disease.